Takentogether, these results support a functional role for GSPT1 in mediating primedresistance to FLT3 inhibitors and suggest that GSPT1 degraders may enhance theefficacy of FLT3 inhibitor therapy in FLT3-ITD-mutated AML. This evidence concerns the gene FLT3 and acute myeloid leukemia.